3,952 research outputs found
Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay
Introduction: We report on a double-blind, vehicle-controlled, single-center confirmatory study with random assignment. The purpose of the study was to investigate the topical bioavailability of different topical corticosteroid formulations in healthy human beings focussing on desoximetasone (DM). Materials and Methods: Two DM 0.25% formulations {[}ointment (DM-o) and fatty ointment (DM-fo, water-free); class III corticosteroids], the corresponding active ingredient-free vehicles and three comparators of different strength {[}clobetasol propionate 0.05% (CP 0.05%), fatty ointment, class IV; hydrocortisone (HC) 1%, fatty ointment, class I, and betamethasone (BM) 0.05%, fatty ointment, class III] were tested using the vasoconstriction assay. The degree of vasoconstriction (blanching) in the treatment field was compared to the one found in untreated control fields using chromametric measurements and clinical assessment. Results/Conclusion: DM-o 0.25%, DM-fo 0.25% and BM 0.05% showed similar vasoconstrictive potential, i.e., clear blanching. In fact, both DM preparations were proven to be non-inferior to BM 0.05%, while CP 0.05% was found a little less active. HC 1.0% and the DM vehicles showed no clear-cut vasoconstrictive effect. No adverse events related to the study medications were observed. Good topical bioavailability of both DM formulations was detected by chromametric measurement and clinical assessment. Copyright (C) 2008 S. Karger AG, Basel
Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases
PURPOSE: Bone metastases secondary to solid tumors increase the risk of skeletal-related events (SREs), including the occurrence of pathological fracture (PF), radiation to bone (RB), surgery to bone (SB), and spinal cord compression (SCC). The aim of this study was to evaluate the impact of SREs on patients' pain, analgesic use, and pain interference with daily functioning.
METHODS: Data were combined from patients with solid tumors and bone metastases who received denosumab or zoledronic acid across three identically designed phase 3 trials (N = 5543). Pain severity (worst pain) and pain interference were assessed using the Brief Pain Inventory at baseline and each monthly visit. Analgesic use was quantified using the Analgesic Quantification Algorithm.
RESULTS: The proportion of patients with moderate/severe pain and strong opioid use generally increased in the 6 months preceding an SRE and remained elevated, while they remained relatively consistent over time in patients without an SRE. Regression analysis indicated that all SRE types were significantly associated with an increased risk of progression to moderate/severe pain and strong opioid use. PF, RB, and SCC were associated with significantly greater risk of pain interference overall. Results were similar for pain interference with emotional well-being. All SRE types were associated with significantly greater risk of pain interference with physical function.
CONCLUSIONS: SREs are associated with increased pain and analgesic use in patients with bone metastases. Treatments that prevent SREs may decrease pain and the need for opioid analgesics and reduce the impact of pain on daily functioning
Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases
PURPOSE: Bone metastases secondary to solid tumors increase the risk of skeletal-related events (SREs), including the occurrence of pathological fracture (PF), radiation to bone (RB), surgery to bone (SB), and spinal cord compression (SCC). The aim of this study was to evaluate the impact of SREs on patients' pain, analgesic use, and pain interference with daily functioning.
METHODS: Data were combined from patients with solid tumors and bone metastases who received denosumab or zoledronic acid across three identically designed phase 3 trials (N = 5543). Pain severity (worst pain) and pain interference were assessed using the Brief Pain Inventory at baseline and each monthly visit. Analgesic use was quantified using the Analgesic Quantification Algorithm.
RESULTS: The proportion of patients with moderate/severe pain and strong opioid use generally increased in the 6 months preceding an SRE and remained elevated, while they remained relatively consistent over time in patients without an SRE. Regression analysis indicated that all SRE types were significantly associated with an increased risk of progression to moderate/severe pain and strong opioid use. PF, RB, and SCC were associated with significantly greater risk of pain interference overall. Results were similar for pain interference with emotional well-being. All SRE types were associated with significantly greater risk of pain interference with physical function.
CONCLUSIONS: SREs are associated with increased pain and analgesic use in patients with bone metastases. Treatments that prevent SREs may decrease pain and the need for opioid analgesics and reduce the impact of pain on daily functioning
Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents
Bone metastases in advanced cancer frequently cause painful complications that impair patient physical activity and negatively affect quality of life. Pain is often underreported and poorly managed in these patients. The most commonly used pain assessment instruments are visual analogue scales, a single-item measure, and the Brief Pain Inventory Questionnaire-Short Form. The World Health Organization analgesic ladder and the Analgesic Quantification Algorithm are used to evaluate analgesic use. Bone-targeting agents, such as denosumab or bisphosphonates, prevent skeletal complications (i.e., radiation to bone, pathologic fractures, surgery to bone, and spinal cord compression) and can also improve pain outcomes in patients with metastatic bone disease. We have reviewed pain outcomes and analgesic use and reported pain data from an integrated analysis of randomized controlled studies of denosumab versus the bisphosphonate zoledronic acid (ZA) in patients with bone metastases from advanced solid tumors. Intravenous bisphosphonates improved pain outcomes in patients with bone metastases from solid tumors. Compared with ZA, denosumab further prevented pain worsening and delayed the need for treatment with strong opioids. In patients with no or mild pain at baseline, denosumab reduced the risk of increasing pain severity and delayed pain worsening along with the time to increased pain interference compared with ZA, suggesting that use of denosumab (with appropriate calcium and vitamin D supplementation) before patients develop bone pain may improve outcomes. These data also support the use of validated pain assessments to optimize treatment and reduce the burden of pain associated with metastatic bone disease
Clinical features, survival times and COX-1 and COX-2 expression in cats with transitional cell carcinoma of the urinary bladder treated with meloxicam
Evaluation of the transformation mechanisms and mechanical properties of ferrite: martensite microalloyed steels
Right Hemisphere Partial Complex Seizures: Mania, Hallucinations, and Speech Disturbances During Ictal Events
A patient with right hemisphere complex partial seizures exhibited extreme emotional lability resembling mania, neologisms resembling those found in fluent aphasia, and hallucinations during ictal periods. The electroencephalographic and clinical findings in this case suggest that cortical and subcortical structures of the right hemisphere may play a role in mediating the expression of language content. RĂSUMĂ Chez un patient prĂsentant des crises partielles complexes de l'hĂmisphĂre droit, nous avons observĂ pendant les crises une labilitĂĂmotionnelle Ăvoquant le diagnostic de manie. des nĂologismes ressemblant Ă ceux de l'aphasie de Wernicke et des hallucinations. Nos constatation EEG et cliniques suggĂrent que les structures corticales et sous-corticales de l'hĂmisphĂre droit peuvent jouer un rĂle dans la mĂdiation de l'expression du contenu linguistique. RESUMEN Un paciente con ataques parciales complejos originados en el hemisferio derecho mostrĂ una labilidad emocional extrema semejante a la mania, neologismos comparables a los que se encuentran en la afasia fluida y alucinaciones durante los perĂodos ictales. Los hallazgos clĂnicos y del EEG en este caso sugieren que estructuras corticales y subcorticales del hemisferio derecho pueden jugar un papel en la funciĂn del contenido del lenguaje expresivo.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/66016/1/j.1528-1157.1988.tb05093.x.pd
Tensor hierarchies, Borcherds algebras and E11
Gauge deformations of maximal supergravity in D=11-n dimensions generically
give rise to a tensor hierarchy of p-form fields that transform in specific
representations of the global symmetry group E(n). We derive the formulas
defining the hierarchy from a Borcherds superalgebra corresponding to E(n).
This explains why the E(n) representations in the tensor hierarchies also
appear in the level decomposition of the Borcherds superalgebra. We show that
the indefinite Kac-Moody algebra E(11) can be used equivalently to determine
these representations, up to p=D, and for arbitrarily large p if E(11) is
replaced by E(r) with sufficiently large rank r.Comment: 22 pages. v2: Published version (except for a few minor typos
detected after the proofreading, which are now corrected
TL1A/DR3 axis involvement in the inflammatory cytokine network during pulmonary sarcoidosis
BACKGROUND:
TNF-like ligand 1A (TL1A), a recently recognized member of the TNF superfamily, and its death domain receptor 3 (DR3), firstly identified for their relevant role in T lymphocyte homeostasis, are now well-known mediators of several immune-inflammatory diseases, ranging from rheumatoid arthritis to inflammatory bowel diseases to psoriasis, whereas no data are available on their involvement in sarcoidosis, a multisystemic granulomatous disease where a deregulated T helper (Th)1/Th17 response takes place.
METHODS:
In this study, by flow cytometry, real-time PCR, confocal microscopy and immunohistochemistry analyses, TL1A and DR3 were investigated in the pulmonary cells and the peripheral blood of 43 patients affected by sarcoidosis in different phases of the disease (29 patients with active sarcoidosis, 14 with the inactive form) and in 8 control subjects.
RESULTS:
Our results demonstrated a significant higher expression, both at protein and mRNA levels, of TL1A and DR3 in pulmonary T cells and alveolar macrophages of patients with active sarcoidosis as compared to patients with the inactive form of the disease and to controls. In patients with sarcoidosis TL1A was strongly more expressed in the lung than the blood, i.e., at the site of the involved organ. Additionally, zymography assays showed that TL1A is able to increase the production of matrix metalloproteinase 9 by sarcoid alveolar macrophages characterized, in patients with the active form of the disease, by reduced mRNA levels of the tissue inhibitor of metalloproteinase (TIMP)-1.
CONCLUSIONS:
These data suggest that TL1A/DR3 interactions are part of the extended and complex immune-inflammatory network that characterizes sarcoidosis during its active phase and may contribute to the pathogenesis and to the progression of the disease
Borcherds Algebras and N=4 Topological Amplitudes
The perturbative spectrum of BPS-states in the E_8 x E_8 heterotic string
theory compactified on T^2 is analysed. We show that the space of BPS-states
forms a representation of a certain Borcherds algebra G which we construct
explicitly using an auxiliary conformal field theory. The denominator formula
of an extension G_{ext} \supset G of this algebra is then found to appear in a
certain heterotic one-loop N=4 topological string amplitude. Our construction
thus gives an N=4 realisation of the idea envisioned by Harvey and Moore,
namely that the `algebra of BPS-states' controls the threshold corrections in
the heterotic string.Comment: 39 page
- âŠ